Login

Limei Han

ORCID: 0009-0003-5918-7930
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5102894609
Research Areas
  • RNA modifications and cancer
  • Cancer-related molecular mechanisms research
  • Gene expression and cancer classification
  • Cancer-related gene regulation
  • Therapeutic Uses of Natural Elements
  • SARS-CoV-2 and COVID-19 Research
  • Lung Cancer Treatments and Mutations
  • SARS-CoV-2 detection and testing
  • COVID-19 Clinical Research Studies

Xinjiang Medical University
 2011-2024

Second Affiliated Hospital of Xinjiang Medical University
 2011-2024

 METTL3-deficiency m6A-dependently degrades MALAT1 to suppress NLRP3-mediated pyroptotic cell death and inflammation in Mycobacterium tuberculosis (H37Ra strain)-infected mouse macrophages
OPENALEX - Publications 
Limei Han Nueramina Tieliwaerdi Xin Li

10.1016/j.tube.2024.102502 article EN Tuberculosis 2024-03-04
 Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19
OPENALEX - Publications 
Rongmeng Jiang Bing Han Wanhong Xu Xiaoying Zhang Chunxian Peng and 39 more Qiang Dang Wei Sun Ling Lin Yuanlong Lin Lingyan Fan Dongqing Lv Lei Shao Ying Chen Yunqing Qiu Limei Han Weixiang Kong Guangming Li Kai Wang Jie Peng Bingliang Lin Zhaowei Tong Xiaobo Lu Lifeng Wang Feng Gao Jiemei Feng Yongxia Li Xiaojun Ma Jinxiang Wang Shanbo Wang Weiliang Shen Chao Wang Kuan Yan Zhenhao Lin Can Jin Long Mao Jia Liu Yulia Kushnareva Olivia Kotoi Zhenhong Zhu Mike A. Royal Mark Brunswick Henry Ji Xiao Xu Hongzhou Lu

BackgroundOlgotrelvir is an oral antiviral with dual mechanisms of action targeting severe acute respiratory syndrome coronavirus 2 main protease (i.e., Mpro) and human cathepsin L. It has potential to serve as a single-agent treatment disease 2019 (Covid-19).MethodsWe conducted phase 3, double-blind, randomized, placebo-controlled trial evaluate the efficacy safety olgotrelvir in 1212 nonhospitalized adult participants mild moderate Covid-19, irrespective risk factors, who were randomly...

10.1056/evidoa2400026 article EN NEJM Evidence 2024-05-28
Coming Soon ...